Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Development and Use of an Application for the Calculation of Diversity Scores of Clinical Trials: A DRIVE Score Calculator

Sam Ranger, Maya Birhiray, Ruemu Birhiray

Blood (2024) 144 (Supplement 1): 7774.

https://doi.org/10.1182/blood-2024-207744

Published: 2024

Journal Articles

Odronextamab Monotherapy in Previously Untreated Patients with High-Risk Follicular Lymphoma (FL): Results of the Safety Lead-in of the Phase 3 Olympia-1 Study

Elizabeth Brem, Wojciech Jurczak, David Belada, Jaime Perez de Oteyza, Aranzazu Alonso Alonso, Fevzi Altuntas, Michał Kwiatek, Joshua Brody, Ernesto Perez Persona, Mustafa Yenerel, Monica Tani, Jingxian Cai, Priya Deshpande, Saleem Shariff, Aafia Chaudhry, Hesham Mohamed, Srikanth Ambati, Ashish Risal, Ruemu Birhiray

Blood (2024) 144 (Supplement 1): 4411.

https://doi.org/10.1182/blood-2024-200080

Published: 2024

Journal Articles

In- class Transition from Parenteral Bortezomib to Oral Ixazomib in Newly Diagnosed Multiple Myeloma: Analysis of US MM-6 By Number of Treatment Cycles Received

Joshua Richter, Saulius Girnius, Ruemu Birhiray, Eric Lloyd, Dasha Cherepanov, Stephen J. Noga, Isabel Nascimento-Ferreira, Robert Rifkin

Blood (2024) 144 (Supplement 1): 4757.

https://doi.org/10.1182/blood-2024-194592

Published: 2024

Journal Articles

A Systematic Review of 72 ASH Plenary and Late Breaking Abstracts for Racial Representation: A Health Equity Call to Action

Maya Birhiray, Sam Ranger, Ruemu Birhiray

Blood (2024) 144 (Supplement 1): 5081.

https://doi.org/10.1182/blood-2024-205723

Published: 2024

Journal Articles

CHOP-Rituximab-Interferon Therapy in Follicular Lmphoma (FL): High Remissions with Reasonable Toxicity.

Ali W. Bseiso, MBBS, William G. Hocking, MD, Richard J. Mercier, MD, Bruce Krawisz, MD, Ruemu Birhiray, MD

Blood (2006) 108 (11): 4731.

https://doi.org/10.1182/blood.V108.11.4731.4731

Published: 2006

NARROW

Development and Use of an Application for the Calculation of Diversity Scores of Clinical Trials: A DRIVE Score Calculator

Odronextamab Monotherapy in Previously Untreated Patients with High-Risk Follicular Lymphoma (FL): Results of the Safety Lead-in of the Phase 3 Olympia-1 Study

In- class Transition from Parenteral Bortezomib to Oral Ixazomib in Newly Diagnosed Multiple Myeloma: Analysis of US MM-6 By Number of Treatment Cycles Received

A Systematic Review of 72 ASH Plenary and Late Breaking Abstracts for Racial Representation: A Health Equity Call to Action

CHOP-Rituximab-Interferon Therapy in Follicular Lmphoma (FL): High Remissions with Reasonable Toxicity.

Email alerts

ASH Publications

American Society of Hematology

Development and Use of an Application for the Calculation of Diversity Scores of Clinical Trials: A DRIVE Score Calculator

Odronextamab Monotherapy in Previously Untreated Patients with High-Risk Follicular Lymphoma (FL): Results of the Safety Lead-in of the Phase 3 Olympia-1 Study

In- class Transition from Parenteral Bortezomib to Oral Ixazomib in Newly Diagnosed Multiple Myeloma: Analysis of US MM-6 By Number of Treatment Cycles Received

A Systematic Review of 72 ASH Plenary and Late Breaking Abstracts for Racial Representation: A Health Equity Call to Action

CHOP-Rituximab-Interferon Therapy in Follicular Lmphoma (FL): High Remissions with Reasonable Toxicity.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only